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Background/introduction
The purpose of this retrospective study was to evaluate
the selection criteria used to determine patient eligibility
for MRgFUS for the treatment of symptomatic uterine
fibroids.
Methods
373 women with symptomatic uterine fibroids were
screened with MRI exams with and without contrast uti-
lizing T2 coronal and axial, T2 fat suppressed sagittal, T1
axial precontrast images, and post contrast fat saturated
images in 3 planes. Patients were initially considered
clinically eligible if they met the standard published
screening criteria/Food and Drug Administration-based
treatment guidelines. These selection criteria were
expanded on a case-by-case basis if it was felt that a NPV
of at least 50% could be obtained or if the patient refused
other treatment approaches (myomectomy, hysterect-
omy, uterine artery embolization).
Results and conclusions
Results: Of the 373 patients (ages 26-61) that underwent
pelvic screening, 188 (51%) were considered eligible and
135 (36%) were excluded for the MRgFUS procedure
based on the published selection criteria. An additional
50 patients (13%) would have been excluded from treat-
ment based on the published criteria, but were given the
opportunity for MRgFUS treatment. Of those 50
patients, 35 patients were treated, with 33 having
fibroids >10 cm, 1 having prior liposuction and 1 having
multiple small fibroids. Of the 33 patients with fibroids
in excess of 10 cm, 11 agreed to have pre treatment
with a GnRH agonist while the other 22 patients refused
all other interventions besides MRgFUS. 135 patients
(36%) were excluded from treatment. The reasons for
exclusion are listed in Table 1 below. Using the FDA-
based treatment guidelines, 188 fibroids were treated
with MRgFUS with an average NPV/fibroid of 66%. Using
expanded selection criteria, an additional 60 fibroids were
treated with an average NPV/fibroid of 56%.
Conclusions: Using the published selection criteria, 51%
of patients who underwent MRI screening were consid-
ered candidates for MRgFUS. An additional 13% of
patients were brought into the treatment arm of the study
after pre-treatment with a GnRH agonist or after consider-
ing patient preference. This individualized approach to
determining patient eligibility resulted in only a slightly
smaller average NPV/fibroid of 56% vs. 66% under the
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Table 1. Patients excluded from MRgFUS treatment
following MRI screening




Fibroid number (>6) 33 45
Possible malignancy 14 19




Fibroid size > 10 cm 9 12
Fibroid size < 2 cm 6 8
Pedunculated fibroid 4 5
Hyperintense T2-weighted signal 5 7
Metal in beampath 3 4
Fibroid location > 12cm from skin 1 2
Obesity {subcutaneous fat layer > 4.0 cm) 1 1
Prior Liposuction 1 1
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published selection criteria. As physicians acquire more
clinical experience with MRgFUS, an expanded selection
criterion may allow more women to benefit from this
more conservative approach to treating uterine fibroids.
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